Financials data is unavailable for this security.
View more
Year on year Diamyd Medical AB 's net income fell 12.13% from a loss of 103.52m to a larger loss of 116.07m despite revenues that grew 20.26% from 454.00k to 546.00k. An increase in the selling, general and administrative costs as a percentage of sales from 4,462.33% to 4,699.27% was a component in the falling net income despite rising revenues.
Gross margin | -7,386.02% |
---|---|
Net profit margin | -75,065.59% |
Operating margin | -76,889.78% |
Return on assets | -68.99% |
---|---|
Return on equity | -84.24% |
Return on investment | -76.65% |
More ▼
Cash flow in SEKView more
In 2023, Diamyd Medical AB increased its cash reserves by 6.49%, or 7.77m. Cash Flow from Financing totalled 86.54m or 15,850.18% of revenues. In addition the company used 110.96m for operations while cash from investing totalled 28.40m.
Cash flow per share | -1.49 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.96 |
---|---|
Tangible book value per share | 1.96 |
More ▼
Balance sheet in SEKView more
Current ratio | 8.87 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.1615 |
---|---|
Total debt/total capital | 0.1391 |
More ▼